Ocumetics Technology Corp. Begins Patient Recruitment for Group Two Clinical Study of Next-Generation Ocumetics Lens

Calgary, Alberta — September 8, 2026 — Leads & Copy — Ocumetics Technology Corp. has initiated patient recruitment for Group Two of its human clinical study for its next-generation accommodating intraocular lens, known as the Ocumetics Lens. This follows encouraging clinical experiences and positive results from the initial group of patients.

The Group Two study, unlike the first group which focused solely on safety, will evaluate the Ocumetics Lens for both safety and its performance in providing near and distance vision. Surgeries for this group are targeted for Fall 2026, with patient recruitment commencing in Mexico City.

The company's clinical facility in Mexico City, which successfully conducted Group One surgeries in Fall 2025, is now identifying and recruiting eligible patients for the upcoming surgeries. Dean Burns, President and CEO of Ocumetics, expressed enthusiasm for the larger Group Two study, highlighting it as another significant milestone in the Ocumetics Lens's clinical development. He stated that recruitment is nearing completion and surgical dates will be scheduled shortly thereafter.

Patients in Group Two will receive the latest-generation Ocumetics Lens, incorporating the company's newest design advancements. This lens will be implanted using an enhanced delivery system developed by Ocumetics. Burns also noted the approaching 12-month follow-up milestone for Group One patients, which will provide crucial longer-term clinical data. He added that the Group Two study represents a forward step with the introduction of the next-generation lens paired with the next-generation delivery system, signifying the continuous evolution of their technology and their dedication to offering a unique solution for patients seeking improved vision across various distances.

The clinical outcomes from Group One met and surpassed the company's expectations concerning the safety, performance, and handling of the Ocumetics Lens. Patient follow-ups are ongoing as part of the company's continuous clinical evaluation, with 12-month visits, a key study milestone, currently in progress.

Ocumetics Technology Corp. is a Canadian research and development firm focused on creating advanced vision correction solutions. The company is currently in the early feasibility study phase for a novel intraocular lens designed to fit within the eye's natural lens compartment, potentially eliminating the need for corrective lenses. This lens is engineered to utilize the eye's natural muscles for focusing, enabling clear vision at all distances without glasses or contact lenses and without a perceptible time lag.

Source: Ocumetics Technology Corp.